J Korean Med Sci.  2020 Dec;35(49):e410. 10.3346/jkms.2020.35.e410.

Current and Future Burden of Periprosthetic Joint Infection from National Claim Database

• Kim HS
• Park JW
• Moon SY
• Lee YK
• Ha YC
• Koo KH

• KMID: 2509594
• DOI: http://doi.org/10.3346/jkms.2020.35.e410

Abstract

Background
Periprosthetic joint infection (PJI) is the most serious complication after total joint arthroplasty. The incidence and burden of PJI in North America have been reported. There might be potential differences according to ethnics and regional practices between western countries and East Asia. Nevertheless, its incidence in East Asia remains unknown. We aimed to evaluate the incidence and economic burden of PJI in Korea and to project the future burden.
Methods
We identified numbers of total hip arthroplasties, total knee arthroplasties and PJIs in Korea from 2010 to 2018 using medical claim data of Korean Health Insurance and Review and Assessment. Annual incidence and medical cost of PJI were calculated. We projected future burden of PJI through 2030 using Quasi-poisson regression model.
Results
The annual incidence of PJI ranged from 2.3% to 2.8% and the average cost per each PJI patient ranged from $4,361 to $6,016. Total annual cost of PJI increased from $8.0 million in 2010 to $18.0 million in 2018 and was projected to exceed $57.0 million by 2030.
Conclusion
The incidence of PJI in Korea is comparable with reported PJI incidence of 2.0%–2.7% in the United States. Our findings would be used for worldwide comparison of PJI epidemiology and establishment of healthcare policies for PJI in East Asia.

Keyword

Total Hip Arthroplasty; Total Knee Arthroplasty; Periprosthetic Joint Infection; Epidemiology; Economic Burden; East Asia

Figure

• 

  Fig. 1 Number of periprosthetic joint infection from 2010 to 2018 in Korea.

• 

  Fig. 2 Trend of PJI from 2010 to 2018 in Korea. (A) Total cost of PJI and (B) the mean personal cost of PJI.PJI = periprosthetic joint infection.

• 

  Fig. 3 Projection of PJI to 2030 in Korea using Quassi-poisson regression model. (A) Projected number of PJI and (B) projected cost of PJI.PJI = periprosthetic joint infection.

Reference

1. Bauer TW, Parvizi J, Kobayashi N, Krebs V. Diagnosis of periprosthetic infection. J Bone Joint Surg Am. 2006; 88(4):869–882. PMID: 16595481.

2. Parvizi J, Zmistowski B, Adeli B. Periprosthetic joint infection: treatment options. Orthopedics. 2010; 33(9):659. PMID: 20839679.

3. Pina M, Gaukhman AD, Hayden B, Smith EL. Three concurrent periprosthetic joint infections: a case report and literature review. Hip Pelvis. 2019; 31(1):57–62. PMID: 30899716.

4. Lamagni T.Epidemiology and burden of prosthetic joint infections. J Antimicrob Chemother. 2014; 69(Suppl 1):i5–10. PMID: 25135091.

5. Tan TL, Kheir MM, Rondon AJ, Parvizi J, George J, Higuera CA, et al. Determining the role and duration of the “antibiotic holiday” period in periprosthetic joint infection. J Arthroplasty. 2018; 33(9):2976–2980. PMID: 29866503.

6. Spivey JC, Guild GN 3rd, Scuderi GR. Use of articulating spacer technique in revision total knee arthroplasty complicated by sepsis: a systematic meta-analysis. Orthopedics. 2017; 40(4):212–220. PMID: 28195606.

7. Wang Q, Goswami K, Kuo FC, Xu C, Tan TL, Parvizi J. Two-stage exchange arthroplasty for periprosthetic joint infection: the rate and reason for the attrition after the first stage. J Arthroplasty. 2019; 34(11):2749–2756. PMID: 31285090.

8. Park HJ, Kim HJ, Kim S, Kim SM, Mun JU, Kim J, et al. Safety of temporary use of recycled autoclaved femoral components in infected total knee arthroplasty: confirming sterility using a sonication method. Clin Orthop Surg. 2018; 10(4):427–432. PMID: 30505410.

9. Huddleston JI, Wang Y, Uquillas C, Herndon JH, Maloney WJ. Age and obesity are risk factors for adverse events after total hip arthroplasty. Clin Orthop Relat Res. 2012; 470(2):490–496. PMID: 21796477.

10. O'Toole P, Maltenfort MG, Chen AF, Parvizi J. Projected increase in periprosthetic joint infections secondary to rise in diabetes and obesity. J Arthroplasty. 2016; 31(1):7–10.

11. Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are we winning or losing the battle with periprosthetic joint infection: trends in periprosthetic joint infection and mortality risk for the medicare population. J Arthroplasty. 2018; 33(10):3238–3245. PMID: 29914821.

12. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012; 27(8 Suppl):61–65.e1. PMID: 22554729.

13. Bozic KJ, Kamath AF, Ong K, Lau E, Kurtz S, Chan V, et al. Comparative epidemiology of revision arthroplasty: failed THA poses greater clinical and economic burdens than failed TKA. Clin Orthop Relat Res. 2015; 473(6):2131–2138. PMID: 25467789.

14. Roth VR, Mitchell R, Vachon J, Alexandre S, Amaratunga K, Smith S, et al. Periprosthetic infection following primary hip and knee arthroplasty: the impact of limiting the postoperative surveillance period. Infect Control Hosp Epidemiol. 2017; 38(2):147–153. PMID: 27834161.

15. Bourne RB, Maloney WJ, Wright JG. An AOA critical issue. The outcome of the outcomes movement. J Bone Joint Surg Am. 2004; 86(3):633–640. PMID: 14996894.

16. Yoon PW, Lee YK, Ahn J, Jang EJ, Kim Y, Kwak HS, et al. Epidemiology of hip replacements in Korea from 2007 to 2011. J Korean Med Sci. 2014; 29(6):852–858. PMID: 24932089.

17. Akindolire J, Morcos MW, Marsh JD, Howard JL, Lanting BA, Vasarhelyi EM. The economic impact of periprosthetic infection in total hip arthroplasty. Can J Surg. 2020; 63(1):E52–6. PMID: 31995337.

18. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008; 466(7):1710–1715. PMID: 18421542.

19. Perfetti DC, Boylan MR, Naziri Q, Paulino CB, Kurtz SM, Mont MA. Have periprosthetic hip infection rates plateaued? J Arthroplasty. 2017; 32(7):2244–2247. PMID: 28318862.

20. Schairer WW, Sing DC, Vail TP, Bozic KJ. Causes and frequency of unplanned hospital readmission after total hip arthroplasty. Clin Orthop Relat Res. 2014; 472(2):464–470. PMID: 23801061.

21. Schairer WW, Vail TP, Bozic KJ. What are the rates and causes of hospital readmission after total knee arthroplasty? Clin Orthop Relat Res. 2014; 472(1):181–187. PMID: 23645339.

22. Garrido-Gómez J, Arrabal-Polo MA, Girón-Prieto MS, Cabello-Salas J, Torres-Barroso J, Parra-Ruiz J. Descriptive analysis of the economic costs of periprosthetic joint infection of the knee for the public health system of Andalusia. J Arthroplasty. 2013; 28(7):1057–1060. PMID: 23523484.

23. Vanhegan IS, Malik AK, Jayakumar P, Ul Islam S, Haddad FS. A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff. J Bone Joint Surg Br. 2012; 94(5):619–623. PMID: 22529080.

24. Wu C, Qu X, Liu F, Li H, Mao Y, Zhu Z. Risk factors for periprosthetic joint infection after total hip arthroplasty and total knee arthroplasty in Chinese patients. PLoS One. 2014; 9(4):e95300. PMID: 24748009.

25. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008; 23(7):984–991. PMID: 18534466.

26. Hackett DJ, Rothenberg AC, Chen AF, Gutowski C, Jaekel D, Tomek IM, et al. The economic significance of orthopaedic infections. J Am Acad Orthop Surg. 2015; 23(Suppl):S1–S7. PMID: 25808964.

27. Kang HY, Yang KH, Kim YN, Moon SH, Choi WJ, Kang DR, et al. Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data. BMC Public Health. 2010; 10(1):230. PMID: 20438644.

28. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293(2):194–202. PMID: 15644546.

29. Sung SK, Lee SG, Lee KS, Kim DS, Kim KH, Kim KY. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther. 2009; 31(6):1309–1320. PMID: 19695396.

30. Lee YK, Byun DW, Jung SM, Kwon HY, Kim HY, Kim SH, et al. Bisphosphonates use and risk of subtrochanteric and diaphyseal femur fractures in Korea: results from the National Claim Registry. Calcif Tissue Int. 2019; 104(3):313–319. PMID: 30446771.

31. Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013; 24(2):707–711. PMID: 22618268.

32. Park SM, Ahn SH, Kim HY, Jang S, Ha YC, Lee YK, et al. Incidence and mortality of subsequent vertebral fractures: analysis of claims data of the Korea National Health Insurance Service from 2007 to 2016. Spine J. 2020; 20(2):225–233. PMID: 31589928.

33. Brochin RL, Phan K, Poeran J, Zubizarreta N, Galatz LM, Moucha CS. Trends in periprosthetic hip infection and associated costs: a population-based study assessing the impact of hospital factors using national data. J Arthroplasty. 2018; 33(7):Suppl. S233–S238. PMID: 29573912.

34. Brochin R, Poeran J, Vig KS, Keswani A, Zubizarreta N, Galatz LM, et al. Trends in periprosthetic knee infection and associated costs: a population-based study using national data. J Knee Surg. Forthcoming 2020. DOI: 10.1055/s-0040-1701516.

35. Korea National Statistical Office. Updated 2020. Accessed September 19, 2020. http://www.kosis.kr/.

36. Kamath AF, Ong KL, Lau E, Chan V, Vail TP, Rubash HE, et al. Quantifying the burden of revision total joint arthroplasty for periprosthetic infection. J Arthroplasty. 2015; 30(9):1492–1497. PMID: 25865815.

37. Xu C, Goswami K, Li WT, Tan TL, Yayac M, Wang SH, et al. Is treatment of periprosthetic joint infection improving over time? J Arthroplasty. 2020; 35(6):1696–1702.e1. PMID: 32192834.

38. Kasahara Y, Majima T, Kimura S, Nishiike O, Uchida J. What are the causes of revision total knee arthroplasty in Japan? Clin Orthop Relat Res. 2013; 471(5):1533–1538. PMID: 23385774.

39. Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, et al. The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria. J Arthroplasty. 2018; 33(5):1309–1314.e2. PMID: 29551303.